Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer

  • Authors:
    • Sebastian Mayer
    • Thalia Erbes
    • Sylvia Timme‑Bronsert
    • Markus Jaeger
    • Gerta Rücker
    • Franciska Kuf
    • Elmar Stickeler
    • Gerald Gitsch
    • Marc Hirschfeld
  • View Affiliations

  • Published online on: June 16, 2017     https://doi.org/10.3892/ol.2017.6406
  • Pages: 2334-2340
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor resistance to endocrine therapy triggers estrogen‑independent cancer progression, which is a major obstacle to the successful treatment of hormone receptor positive breast cancer (BC). The underlying molecular mechanisms of endocrine resistance are not fully understood yet. The matricellular protein cysteine‑rich angiogenic inducer 61 (Cyr61) is associated with tumor invasiveness and the induction of tumorigenesis in various malignancies in vivo and the induction of estrogen‑independence and endocrine therapy resistance in BC. The present study evaluated the potential effects and clinical relevance of Cyr61 expression levels in 67 patients with primary non‑metastatic BC. Immunohistochemical analysis of formalin‑fixed paraffin‑embedded tissue sections was performed, and the association between Cyr61 protein expression and clinicopathological factors and survival was analyzed. Cyr61 overexpression was revealed to be significantly associated with a positive estrogen receptor (ER)/progesterone receptor (PR) status (P=0.016) and to the molecular subtype of BC (P=0.039). Compared with patients without Cyr61 overexpression, patients with Cyr61 overexpression exhibited an increased recurrence rate (30.6 vs. 22.6%) and decreased long‑term survival (10‑year overall survival, 62.9 vs. 69.7%); however, these associations did not reach statistically significant levels in Cox regression model analysis. Similar results were identified in the subgroup analysis of patients with ER/PR positive BC. These results indicate that Cyr61 serves a role in the development of endocrine therapy resistance in BC and is thus a potential therapeutic target to overcome endocrine therapy resistance. However, additional long‑term survival analyses with large patient populations are required.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mayer S, Erbes T, Timme‑Bronsert S, Jaeger M, Rücker G, Kuf F, Stickeler E, Gitsch G and Hirschfeld M: Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer. Oncol Lett 14: 2334-2340, 2017
APA
Mayer, S., Erbes, T., Timme‑Bronsert, S., Jaeger, M., Rücker, G., Kuf, F. ... Hirschfeld, M. (2017). Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer. Oncology Letters, 14, 2334-2340. https://doi.org/10.3892/ol.2017.6406
MLA
Mayer, S., Erbes, T., Timme‑Bronsert, S., Jaeger, M., Rücker, G., Kuf, F., Stickeler, E., Gitsch, G., Hirschfeld, M."Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer". Oncology Letters 14.2 (2017): 2334-2340.
Chicago
Mayer, S., Erbes, T., Timme‑Bronsert, S., Jaeger, M., Rücker, G., Kuf, F., Stickeler, E., Gitsch, G., Hirschfeld, M."Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer". Oncology Letters 14, no. 2 (2017): 2334-2340. https://doi.org/10.3892/ol.2017.6406